Circulating MicroRNA Signature for the Diagnosis of Very High-Risk Prostate Cancer*
This chapter reports the identification of a molecular signature using the Scano-miR profiling platform based on the differential expression of circulating microRNAs (miRNA, miR) in serum samples specific to patients with very high-risk (VHR) prostate cancer (PCa). Serum microRNAs have emerged as potential noninvasive biomarkers to diagnose PCa, the most common noncutaneous malignancy among Western men. However, intermediate grades of PCa cannot be distinguished from aggressive forms using current miRNA signatures due to the heterogeneity of PCas. By studying serum miRNAs of PCa using the ScanomiR bioassay, the chapter identifies a unique molecular signature specific for very high-risk aggressive PCa. This molecular signature assists in differentiating patients who may benefit from therapy from those who can be closely monitored on active surveillance. The chapter seeks to determine the miRNA expression of VHR PCa and validate this expression pattern in men with differing PCa aggressiveness.